US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
pharma
Accord Healthcare Pty
Accord Healthcare Pty.
Accord Healthcare Pty drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
SCARBOROUGH, AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- SCARBOROUGH, AU
- Programs
- 0
- Drugs
- 7
- Patents
- 0
Accord Healthcare Pty pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Accord Healthcare Pty drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Accord Healthcare Pty in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pegfilgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
topotecan
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Accord Healthcare Pty's portfolio. Mechanism: DNA topoisomerase I, mitochondrial inhibitor.
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor